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Abstract
Purpose: To track the dosimetric changes for similar dose prescriptions, whendose calculation algorithms are upgraded in the treatment planning system (TPS).Clinically significant representations of the treatment outcomes are used toprovide interpretable data for radiation oncologists, as the equivalent uniform dose(EUD), the tumor control probability (TCP), the late toxicity as normal tissuecomplication probability (NTCP) and the uncomplicated tumor control probability(UTCP) scores. Results are presented and discussed in a clinical perspective.
Methods: Ten lung cancer patients were included in this study. For each patient,five treatment plans were generated. The doses were calculated using AnisotropicAnalytical Algorithm (AAA) and both Acuros XB (AXB) dose reporting modes:dose-to-medium AXB D(m,m) and dose-to-water AXB D(w,m). In plans 1, 2 and 3,the doses were calculated respectively with AAA, AXB D(m,m) and AXB D(w,m)using exactly the same prescription dose and beam set-up. The doses in plans 4 and5 were calculated using both AXB dose reporting modes using, as input, the samenumber of monitor units (MUs) as yielded by AAA, with the same beam set-up. TheEUD, TCP and NTCP were computed using the assumed radiobiological parametersfrom literature. The Wilcoxon paired test was used to calculate p-values. Results:Using the same prescription dose, TCP values were higher with AXB than with AAA,and corresponding UTCP scores were 1-2% better with p < 0.05. In addition,absolute NTCP values were slightly increased with AXB. Both AXB dose reportingmodes yielded comparable lower TCP and NTCP values (again in the order of1-2%) than with AAA, when using same MU numbers as with AAA. Conclusion:Compared to AAA, taken as reference, both AXB dose reporting modes yieldedbetter results. AAA showed very close values to AXB D(w,m), but it is difficult togive recommendation between D(w,m) and D(m,m) yet, due to the lack ofrecommended radiobiological parameters associated with these dose reportingmodes. We suggest doing experimental and modelling studies to determine the realradiobiological effects in both targets and organs at risks. Should the differences besubstantial in some conditions and relevant to clinical practice, discussions
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regarding dose prescription and optimization of the tolerance doses to OAR shouldbe undertaken between medical physicists and radiation oncologists.
Keywords: Acuros XB, TCP, NTCP, UTCP.
1. IntroductionDifferent dose calculation algorithms result in variabledose distributions that may be relevant to patients.Moreover, the most recent algorithms, having improvedaccuracy, often result in more dose heterogeneityinfluencing radiotherapy efficacy and safety, for bothtumors and normal tissues, respectively. Algorithms,such as Analytical Anisotropic Algorithm (AAA)1-4 andrecent Acuros XB algorithm (AXB), both implemented inEclipse™ treatment planning system (TPS) (VarianMedical Systems, Inc., Palo Alto, CA), are close to, orbased on, Monte Carlo methods. AXB has two dosereporting modes: dose-to-water in medium (D(w,m)) ordose-to-medium in medium (D(m,m)). Historically, dosecalculation algorithms were based on the dose-to-waterassuming an homogeneous water target (D(w,w)). Then,the D(w,m) was introduced in conventionalradiotherapy to take into account heterogeneities, suchas lung and bone. Thus, the clinical validation of theD(m,m) mode may be an issue because the reference forclinical data are based on D(w,w). The questionregarding the extent of the dose prescriptionadjustments has been brought out for some years, whenthe transition from algorithms of type (A) to type (B)were carried out5,6. Discussions and recommendationsbased on dosimetric, statistical and radiobiologicalcriteria to ensure a safe transition have beenpublished5,6.In this context, 3D conformal radiation therapy (3DCRT)is a convenient technique to evaluate the real impact of achange of the dose calculation algorithm7. 3DCRT allowsthe use of a minimal number of technical parameters,conversely to more complicated techniques, such asintensity-modulated radiotherapy (IMRT) andvolumetric modulated radiotherapy (VMAT) orstereotactic body radiotherapy (SBRT). The latter isparticularly challenging due to small fields andelectronic disequilibrium. Thus, we used 3DCRT planevaluations that could be performed withstraightforward physical parameters derived from dosevolume histograms (DVH).At present, radiobiological modelling can be used tocompare and rank radiotherapy plans as well as toperform in silico prediction of clinical outcomes such astumor control probability (TCP) and normal tissuecomplication probability (NTCP). In addition, multipleparameters can be integrated into one more clinicallyrelevant score, such as: the uncomplicated tumor controlprobability (UTCP)8, which represents tumor controlprobability in the absence of treatment-related
complications. The UTCP score was recently proposedfor the estimation of the quality of life (Qol), therebyproviding the most integrated information by taking intoaccount radiation-induced side effects and theirconsequences on the wellbeing of an individual for agiven cancer site9. UTCP aims to be a sensitive score ofthe global clinical impact resulting from a change of dosecalculation algorithm. It should be evaluated withcaution with respect to the radiobiological models andparameters used.To the best of our knowledge, no previous study hasbeen published on lung cancer treatment plans using theUTCP to evaluate the potential impact of AXB dosereporting modes on clinical radiotherapy outcomes,compared to AAA taken as reference. In this study, weraise two questions: firstly, what should we knowregarding dose prescription adjustment, when movingfrom AAA to AXB? Secondly, what should one be awareof when considering radiobiological assessment forD(m,m) or D(w,m)?Thus, the primary aim of this study is to highlight thedifferences in real delivered dose from DVH translatedinto equivalent uniform dose (EUD) for lungradiotherapy treatment plans. The secondary aim is tocompare TCP, NTCP and UTCP scores between plansthat exhibit differences in dose distributions. It ishypothesized that UTCP scores could predict the globalQol and could be used as a clinical indicator to safelymove from AAA to AXB.
2. Methods and Materials
2.1. Dose calculation modelsThe dose calculations were performed using AAA andAXB with both dose reporting modes. The algorithmswere integrated in version 13.5 of Varian Eclipse™ TPS.In both algorithms, heterogeneity corrections areperformed. In AAA, three sub-sources are modeled,including primary photons, extra-focal photons andelectron contamination. AXB uses a sophisticatedtechnique to solve the Linear Boltzmann transportequation (LBTE) and it directly accounts for the effectsof heterogeneities in patient dose calculations10-16.
2.2. Clinical cases and treatment planningTen patients with lung cancer were included in thisstudy. Radiation oncologists delineated the targetstructures and organs at risk (OARs). The total doseprescribed to the planning target volume (PTV) was 54
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to 66 Gy with a daily dose of 1.8 or 2 Gy to be treated in30 or 33 fractions. The prescription was done on the95% isodose that encompassed the whole PTV. The doseconstraints to the OARs are based on the internationalrecommendations. Two methods were used to comparethe treatment plans7:
 Method 1: this method requires a fixedprescription dose and normalization withidentical beam arrangements. For thisobjective, for each patient a set of three planswas generated using AAA, AXB D(m,m) and AXBD(w,m).
 Method 2: this method requires a fixed numberof monitor units (MUs) and normalizationobtained from AAA to re-calculate the dosedistribution with AXB. For this objective, plans4 and 5 were generated. Dose distributionswere re-calculated with AXB D(m,m) and AXBD(w,m) using the number of MUs obtained fromAAA as input and the same beam arrangements.Thus, reliable plan comparisons wereperformed to assess the effect of dosecalculation for each field.The Figure 1 shows the method used to compareradiotherapy plans.
2.3. Radiobiological modeling
2.3.1. Equivalent uniform dose
Cumulative DVHs were calculated for all plans, and thenconverted into differential DVH. The EUD modelproposed by Niemierko 1997, was used to calculate theTCP and NTCP17,18. According to Niemierko’s model,EUD is defined as:
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where (nf) is the number of fractions. The α/β is thetissue-specific LQ parameter taken from QUantitativeAnalysis of Normal Tissue Effects in the Clinic(QUANTEC) recommendations20,21,22.
Figure 1: The two normalization methods (prescription dose, left panel; and the MU numbers, right panel) used tocompare lung radiotherapy plans with 3DCRT.
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Table 1: Radiobiological parameters for TCP and NTCP for selected OARs in this study.Structures Endpoint TCD50/TD50 [Gy] α/β a γ50PTV Tumor control TCD50 = 51.24 10.0 -10.0 0.83Lung-PTV Pneumonitis TD50 = 29.14 4.020 1.0 2.0Heart Pericarditis TD50 = 48.0 2.521 3.1 3.0Esophagus Clinical stricture/ perforation TD50 = 68.0 10.022 18.0 4.0
2.3.2. Tumor control probabilityNiemierko’s EUD-based TCP is defined as:
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where TCD50 is the dose to control 50% of the tumors,when the tumors are homogeneously irradiated. Thefactor (γ50) describes the slope of the dose-responsecurve. The parameters for TCD50and γ50 for target weretaken from Okunieff et al. considering macroscopictumor23. For lung tumors: α/β = 10 Gy and a = -10 wereselected for this study.
2.3.3. Normal tissue complication probabilityNiemierko’s EUD based NTCP is defined as:
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where TD50 is the tolerance dose for 50% complicationrate of the normal organ. TD50 for lung was taken fromHedin E et al. 2013, where the parameter waswell-adapted for AAA algorithm24 For the heart andesophagus, the TD50 were taken from Emami–Burmanparameters25. The value of TD50 for each organ alsoreflects the level of toxicity to be modelled. The values ofparameters (γ50) and (a) [in EUD] were taken fromNiemierko’s model. Table 1 shows the radiobiologicalparameters for target and OARs considered in thisstudy26,27.
2.3.4. Uncomplicated tumor control probabilityIn order to quantify the benefit and toxicity balanceof the treatment for a given patient, the UTCP iscalculated as28:



3
1
)1(*
i
NTCPTCPUTCP (5)where (i) = 3 according to the three OARs, includinghealthy lung, heart and esophagus.
2.4. Statistical analysisThe same CT scan for each patient was used to generate5 different treatment plans. Then, the dose wasrecalculated with AAA and both AXB dose reporting
modes. Thus, there was a relationship for each patientbetween the dosimetric data from reference plan, AAA,and the tested plans with both AXB dose reportingmodes. In this case, different sets of dosimetric data areused as input to estimate EUD, TCP, NTCP and UTCP fora given patient. Thus, the Wilcoxon signed rank test wasused to calculate the p-value, considering p < 0.05 as asignificance difference29. The null hypothesis means thatradiobiological indices in all plans do not significantlydiffer from 0. In addition, the statistical correlationbetween predicted radiobiological indices obtained fromAXB with both dose reporting modes, and with AAA, wasevaluated using Spearman’s correlation coefficient(ρ-value).
3. Results
3.1. Tumor control probabilityThe EUD values in plans 2 and 3 using AXB D(m,m) andAXB D(w,m) were increased. They predicted more doseto the target compared with AAA, on average 0.4% (1.6SD) and 0.1% (1.2 SD), respectively. Thus, TCP values inplans 2 and 3 were also increased, on average by 0.8%(2.2 SD) and 0.4% (1.4 SD), respectively, as TCP dependson EUD. The data did not show any significantdifference, when comparing AAA with both AXB dosereporting modes, with p > 0.05. In addition, the datashowed a strong correlation for both AXB dose reportingmodes vs. AAA, with ρ > 0.85. Plans 4 and 5 were morerealistic for the comparison of both algorithms. Usingthe same MUs as with AAA as input, EUD as well as TCPvalues were lower than with AAA by 1.0 % (1.3 SD) and0.2 % (1.5 SD) using AXB D(m,m) and AXB D(w,m),respectively. The Wilcoxon test indicated no significantdifference between TCP calculated from AAA with bothAXB dose reporting modes. In addition, the data showeda strong correlation for both AXB dose reporting modesvs. AAA, with ρ > 0.98.Figure 2 shows the average values for EUD and TCP fromall plans using AAA and both AXB dose reporting modes.It can be seen, compared with AAA, that the AXB showslarger EUD values leading to larger TCP. Conversely, theaverage TCP values in plans 4 and 5 using the same MUas with AAA were slightly lower compared to AAA.However, to conclude about which is the better plan, oneshould consider the most accurate algorithm being AXB.Using the same MUs as with AAA to recalculate DVHwith AXB, in the present study, AAA certainlyoverestimates the TCP value by 1-2%.
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Figure 2: The average values for EUD (upper panel) and TCP (lower panel) from all lung cancer treatment plans, createdusing a 3DCRT technique with AAA and both AXB dose reporting modes. The TCP values were normalized to 100% vs. AAAconsidered as the reference, to better estimate the shift in TCP values.
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Table 2: The average values for EUD and NTCP from all plans as well as p-values for NTCP. The doses in plans 1, 2 and 3 werecalculated, respectively with AAA and both AXB dose reporting modes using the same prescription dose. The doses in plan 4and 5 were calculated with AXB using MUs from AAA.AAAPlan 1 AXB D(m,m)Plan 2 AXB D(w,m)Plan 3 AXB D(m,m)Plan 4 AXB D(w,m)Plan 5Lung EUD Gy 10.7[2.1;13.5] 10.9[2.1;13.7] 10.8[2.1;13.7] 10.7[2.0;13.4] 10.7[2.0;13.4]NTCP % 0.08[0.0;0.21] 0.1[0.0;0.24] 0.1[0.0;0.23] 0.08[0.0; 0,2] 0.08[0.0;0.2]p-values - 0.004 0.2 0.37 0.01Heart EUD Gy 20.5[0.3;32.5] 20.4[0.3;33.5] 20.6[0.3;33.8] 20.1[0.3;32.7] 20.6[0.3;33.3]NTCP % 0.25[0.0;0.9] 0.27[0.0;1.3] 0.3[0.0;1.4] 0.3[0.0;1.4] 0.3[0.0;1.2]p-values 0.2 0.8 0.08 0.6Esophagus EUD Gy 53.9[44.4;58.6] 53.6[44.0;58.0] 53.9[44.7;58.1] 52.9[43.6;57.5] 53.8[44.7;58.5]NTCP % 3.7[0.1;8.5] 3.3[0.1;7.3] 3.6[0.1;7.4] 2.8[0.1;6.4] 3.6[0.1;8.4]p-values - 0.06 0.04 0.002 0.002
Figure 3: UTCP with average values from AAA and both AXB modes for lung cancer treatment plans, created by 3DCRTtechnique.
3.2. Normal tissue complication probabilityThe EUD values in plans 2 and 3 using both AXB dosereporting modes were increased for healthy lung. Theypredicted larger NTCP compared with AAA. Table 2shows the average values for EUD and NTCP from allplans. It can be seen that the NTCP from plans 4 and 5were close to AAA. Using the same MUs from AAA tore-calculate the DVH with both AXB dose reportingmodes, it showed much similar NTCP values.
3.3. Uncomplicated tumor control probabilityFigure 3 shows the UTCP with average values from allseries of plans. The data showed no significantdifference, when comparing AAA with AXB, with p >0.05. In addition, the data showed a strong correlationfor both AXB modes vs. AAA, with ρ = 0.99.
4. DiscussionIn this radiobiological evaluation, we compared twodose calculation algorithms (AXB vs. AAA) that wereused to calculate dose distributions in lung cancertreatment plans, created using a 3DCRT technique. Inthis study, both AXB dose reporting modes and AAAdemonstrated comparable TCP values within 1-2%,using the same prescription dose. Our results areconsistent with those found by Liang et al. 2016, forIMRT30. However, the difference between the results ofAXB and AAA may become clinically less significantusing the same MUs as with AAA. The use of AXB D(w,m)that considers water equivalence for the voxel dosecalculation, the results were very similar. Thus, thechoice of the AXB dose reporting mode plays some role:firstly in the calculation of the delivered dose in MUs asstandard indicator to compare dose calculation
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algorithms31 and secondly, the delivered dose willinfluence radiotherapy outcomes. The advantage of3DCRT, as a reference technique, is to compare the newalgorithm without introducing many parametersinfluencing the results. In this context, it is interesting tonote that the impact of dose calculation may differdepending on treatment delivery techniques, beamorientation and prescription dose method. Thus, it isessential to further investigate the output of both AXBdose reporting modes, for any treatment deliverytechniques, to measure or estimate more accurately thedose modifications. The objective is to avoid theover/under irradiation of the patients, which couldtranslate into variations of TCP, NTCP and UTCP. Therisk of over irradiation is likely to increase the normaltissue toxicities, NTCP, while under coverage wouldincrease the risk of local recurrence.
4.1. Medical decision: D(m,m) or D(w,m) vs. AAAThe choice of the dose reporting modes is a critical issue,because dose distribution is the basic information for allradiobiological models. However, moving from AAA toAXB D(w,m), using 3DCRT, would most probablyproduce similar results regarding treatment plan qualityor UTCP as a surrogate parameter, assuming that theradiobiological parameters are well-adapted. Thus, AXBD(w,m) algorithm could be validated for clinical use. Inaddition, full MC simulations are encouraged as averification method for some situations withheterogeneous media such as lung, bone and high-Zmaterials32. However, the implementation of D(m,m)needs more relevant radiobiological data to refine andconfirm the predicted TCP and NTCP. The cohort used inthis study is small (n = 10). However, this is the firststudy proposing a radiobiological approach for thechoice between D(m,m) and D(w,m). Thus, we suggestdoing several studies using the approach proposed inthis study to determine the effect on dose distributionsfor both targets and OARs for various anatomicalregions. If substantial differences would be discovered, adiscussion regarding the dose prescription and thetolerance doses should take place among physicists andoncologists about the need to adjust or not theprescriptions, as well as, to optimize the OARsprotection, to keep on with the same clinical results.
4.2. Caution with radiobiological parametersEarly radiation-induced toxicity during the radiotherapycourse can be observed and may result in treatmentinterruption and protraction. However, it is a verydifferent biological process than delayed toxicity andradiobiological models have to be specifically tuned forearly or late NTCP and adapted to the level of severity(grade 1 to 4). For example, acute esophagitis isobserved in a large proportion of patients treated forlung cancer while NTCP model estimates late toxicityrates of about 3% (Table 2)33,34.
For delayed, or late toxicity, the probability and theseverity of toxicity depend on the delivered dose to theOAR itself. The delivered dose could be translated intoa EUD value using differential DVH. Thus, increasingEUD could increase NTCP and severity of toxicities. Inthis study, we simulated the dose-effect relationshipprobability using the NTCP model that integrates theEUD concept. Historically the NTCP models were tunedwith high TD50, to predict for severe toxicity and thus toavoid dangerous or disabling damages to the patients.Available parameters, listed in Table 1, were used,assuming they are adapted for this comparison, i.e. tosevere late effects; although we could not find in theliterature the radiobiological parameters adapted to AXBD(m,m).Only a few studies in the literature evaluated the TD50for NTCP for lung according to algorithms of types (A) or(B)24. Thus, it is relevant to mention that previousradiobiological modeling studies for lung cancer,applying EUD or Lyman-Kutcher-Burman (LKB)approach, have used TD50 = 24 Gy, withoutheterogeneity correction. More recently, this value wasre-estimated for AAA35, yielding a higher value fullyconsistent with the underestimation of the real dose bythe former algorithms of type (A). This is a critical issue,since using TD50 = 24 Gy instead of 29.14 Gy, wouldincrease the NTCP in absolute value. Since we do nothave sufficient clinical data to ascertain a refinedabsolute estimation of NTCP, it is better, presently, touse ΔNTCP. However, if the comparison is based on EUDand considering that, the increase of EUD wouldincrease the NTCP, we can confirm that the applicationof the same prescription dose, when moving from AAAto AXB would increase EUD for lung, heart andesophagus.In this study to make a reliable estimation, theradiobiological parameters for OARs were taken fromLKB35,36, as well as TD50 assumed for AAA for lung wasused. It should be clear that, using more adaptedradiobiological parameters is the optimal approach tocompare, in silico, the radiotherapy outcomes, when anew algorithm is implemented. In this regard, it isimportant to note that there are some limitations thatmay influence the interpretation of the predicted results.Firstly, the comparison is based on patients reallytreated with AAA and virtually planned with AXB. Thus,we used the same cohort, but in reality, the cohort wouldbe different at the time of real clinical use of AXB.Secondly, there are studies showing that the relationshipbetween dose distribution parameters and side effectsmight differ among different patient populations37,38. Itcannot be excluded that the patient anatomy and lungdensity would influence the dose distribution and thus,would indirectly influence the radiotherapy outcomepredictions and a small population may not berepresentative of these hypothetic conditions.
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5. ConclusionWe compared TCP and NTCP from AAA and both AXBdose reporting modes using radiobiological parametersfrom literature. As a whole, the step from AAA to AXB ismuch smaller than the step between type (A) to type (B)algorithms. In this instance, the change from type (A)directly to type (C), non-MC or MC algorithm would bedangerous without a similar study, as reported in thispaper39. However, a large cohort with cumulated data isneeded to reduce the uncertainties in the assumptionsused to predict TCP and NTCP, as well as to improve thecalibration of the radiobiological models. The use ofradiobiological parameters assumed from clinicalexperience derived from D(w,m) to estimate TCP andNTCP with D(m,m) would produce uncertaintyregarding the clinical outcomes.
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